转移性胰腺癌-话题@MedSci

#转移性胰腺癌#

26篇内容 | 1805人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2224201, encodeId=6c4b222420105, content=<a href='/topic/show?id=10dc3890e66' target=_blank style='color:#2F92EE;'>#吉西他滨#</a> <a href='/topic/show?id=2916e177389' target=_blank style='color:#2F92EE;'>#白蛋白结合型紫杉醇#</a> <a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, objectTitle=减少化疗，疗效相当，还更安全！《柳叶刀》子刊：转移性胰腺癌新治疗策略, objectType=article, longId=841841, objectId=aded84184152, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240905/1725498482877_8538692.jpg, objectUrl=/article/show_article.do?id=aded84184152, replyNumber=0, likeNumber=83, createdTime=2024-09-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=aded84184152, moduleTitle=减少化疗，疗效相当，还更安全！《柳叶刀》子刊：转移性胰腺癌新治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aded84184152)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1390238, encodeId=f46513902382c, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, objectTitle=Radiology：CT+CA19-9的强强联手：非转移性胰腺癌的治疗反应评估, objectType=article, longId=735694, objectId=74d3e3569400, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74d3e3569400, replyNumber=0, likeNumber=103, createdTime=2022-08-13, rootId=0, userName=124986d2m09暂无昵称, userId=a5002500055, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74d3e3569400, moduleTitle=Radiology：CT+CA19-9的强强联手：非转移性胰腺癌的治疗反应评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74d3e3569400)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1390237, encodeId=e3ba139023ec4, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, objectTitle=Radiology：CT和CA19-9对非转移性胰腺癌治疗效果的评估, objectType=article, longId=731928, objectId=fea2e3192803, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fea2e3192803, replyNumber=0, likeNumber=120, createdTime=2022-07-11, rootId=0, userName=124986d2m09暂无昵称, userId=a5002500055, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fea2e3192803, moduleTitle=Radiology：CT和CA19-9对非转移性胰腺癌治疗效果的评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fea2e3192803)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1390236, encodeId=cac9139023676, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, objectTitle=ASCO：转移性胰腺癌患者化疗免疫治疗后生物特征与生存率的关系, objectType=article, longId=728269, objectId=0f7ce282691b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f7ce282691b, replyNumber=0, likeNumber=73, createdTime=2022-06-01, rootId=0, userName=124986d2m09暂无昵称, userId=a5002500055, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f7ce282691b, moduleTitle=ASCO：转移性胰腺癌患者化疗免疫治疗后生物特征与生存率的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f7ce282691b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1390235, encodeId=0a651390235fe, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, objectTitle=Clin Cancer Res：PARP抑制剂Veliparib联合优化的FOLFIRI作为二线治疗转移性胰腺癌, objectType=article, longId=221813, objectId=789422181362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=789422181362, replyNumber=0, likeNumber=96, createdTime=2021-12-11, rootId=0, userName=124986d2m09暂无昵称, userId=a5002500055, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=789422181362, moduleTitle=Clin Cancer Res：PARP抑制剂Veliparib联合优化的FOLFIRI作为二线治疗转移性胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=789422181362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1390234, encodeId=a2d3139023401, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, objectTitle=ESMO Open：Nab-紫杉醇/吉西他滨和FOLFIRINOX作为一线序贯治疗转移性胰腺癌, objectType=article, longId=221332, objectId=bde422133214, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bde422133214, replyNumber=0, likeNumber=83, createdTime=2021-12-01, rootId=0, userName=124986d2m09暂无昵称, userId=a5002500055, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bde422133214, moduleTitle=ESMO Open：Nab-紫杉醇/吉西他滨和FOLFIRINOX作为一线序贯治疗转移性胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bde422133214)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1390233, encodeId=dd0e1390233f0, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, objectTitle=Oncologist: FOLFOX方案联合dasatinib（达沙替尼）一线治疗转移性胰腺癌患者的疗效和安全性, objectType=article, longId=221323, objectId=976a22132323, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=976a22132323, replyNumber=0, likeNumber=75, createdTime=2021-12-01, rootId=0, userName=124986d2m09暂无昵称, userId=a5002500055, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=976a22132323, moduleTitle=Oncologist: FOLFOX方案联合dasatinib（达沙替尼）一线治疗转移性胰腺癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=976a22132323)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1390232, encodeId=1e63139023224, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, objectTitle=JNCCN：真实世界研究中转移性胰腺癌患者一线和二线治疗的预后, objectType=article, longId=216799, objectId=0e7f216e9991, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e7f216e9991, replyNumber=0, likeNumber=70, createdTime=2021-09-09, rootId=0, userName=124986d2m09暂无昵称, userId=a5002500055, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e7f216e9991, moduleTitle=JNCCN：真实世界研究中转移性胰腺癌患者一线和二线治疗的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e7f216e9991)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1390231, encodeId=fea9139023182, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, objectTitle=Eur J Cancer：3期| 改良版FOLFIRINOX vs S-1方案二线治疗吉西他滨难治性转移性胰腺癌的疗效, objectType=article, longId=216768, objectId=ddae216e6887, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddae216e6887, replyNumber=0, likeNumber=83, createdTime=2021-09-08, rootId=0, userName=124986d2m09暂无昵称, userId=a5002500055, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddae216e6887, moduleTitle=Eur J Cancer：3期| 改良版FOLFIRINOX vs S-1方案二线治疗吉西他滨难治性转移性胰腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddae216e6887)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1390230, encodeId=16261390230a0, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, objectTitle=J Clin Oncol：转移性胰腺癌的一线治疗该何去何从？, objectType=article, longId=214658, objectId=3d7e214658f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d7e214658f0, replyNumber=0, likeNumber=72, createdTime=2021-07-24, rootId=0, userName=124986d2m09暂无昵称, userId=a5002500055, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d7e214658f0, moduleTitle=J Clin Oncol：转移性胰腺癌的一线治疗该何去何从？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d7e214658f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1390229, encodeId=df2b13902295e, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, objectTitle=JCO：Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效, objectType=article, longId=207010, objectId=0c9920e0107e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c9920e0107e, replyNumber=0, likeNumber=74, createdTime=2021-02-11, rootId=0, userName=124986d2m09暂无昵称, userId=a5002500055, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c9920e0107e, moduleTitle=JCO：Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c9920e0107e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1390228, encodeId=93aa139022849, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, objectTitle=Lancet Oncol：CD40激动性单克隆抗体APX005M联合化疗治疗转移性胰腺癌, objectType=article, longId=205427, objectId=c5f320542e03, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5f320542e03, replyNumber=0, likeNumber=96, createdTime=2021-01-08, rootId=0, userName=124986d2m09暂无昵称, userId=a5002500055, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5f320542e03, moduleTitle=Lancet Oncol：CD40激动性单克隆抗体APX005M联合化疗治疗转移性胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5f320542e03)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1390227, encodeId=9e74139022e7d, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, objectTitle=FDA授予伊立替康脂质体（ONIVYDE）快速通道指定，用于转移性胰腺癌的一线联合治疗, objectType=article, longId=196066, objectId=8dab1960666a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dab1960666a, replyNumber=0, likeNumber=76, createdTime=2020-06-19, rootId=0, userName=124986d2m09暂无昵称, userId=a5002500055, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dab1960666a, moduleTitle=FDA授予伊立替康脂质体（ONIVYDE）快速通道指定，用于转移性胰腺癌的一线联合治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dab1960666a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1390226, encodeId=14a913902266d, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, objectTitle=NantKwest的NK细胞疗法联合T细胞激活剂在转移性胰腺癌患者的早期临床试验中，将肿瘤根除, objectType=article, longId=186458, objectId=5e3118645817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e3118645817, replyNumber=0, likeNumber=101, createdTime=2020-01-19, rootId=0, userName=124986d2m09暂无昵称, userId=a5002500055, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e3118645817, moduleTitle=NantKwest的NK细胞疗法联合T细胞激活剂在转移性胰腺癌患者的早期临床试验中，将肿瘤根除, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e3118645817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1390225, encodeId=3bc11390225e7, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, objectTitle=BioLineRx宣布其CXCL4拮抗剂BL-8040与Keytruda联合治疗转移性胰腺癌的2b临床活性, objectType=article, longId=182514, objectId=bed218251491, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bed218251491, replyNumber=0, likeNumber=85, createdTime=2019-11-08, rootId=0, userName=124986d2m09暂无昵称, userId=a5002500055, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bed218251491, moduleTitle=BioLineRx宣布其CXCL4拮抗剂BL-8040与Keytruda联合治疗转移性胰腺癌的2b临床活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bed218251491)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1390224, encodeId=48331390224c2, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, objectTitle=JAMA Oncol：紫杉醇、吉西他滨以及顺铂治疗转移性胰腺癌, objectType=article, longId=180724, objectId=1d0c180e24c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d0c180e24c3, replyNumber=0, likeNumber=91, createdTime=2019-10-10, rootId=0, userName=124986d2m09暂无昵称, userId=a5002500055, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d0c180e24c3, moduleTitle=JAMA Oncol：紫杉醇、吉西他滨以及顺铂治疗转移性胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d0c180e24c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1390223, encodeId=2ae8139022339, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, objectTitle=2019 ESMO胃肠癌世界大会：奥拉帕尼维持治疗改善了BRCA突变的转移性胰腺癌患者的无进展生存期, objectType=article, longId=175101, objectId=26291e5101bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26291e5101bd, replyNumber=0, likeNumber=91, createdTime=2019-07-11, rootId=0, userName=124986d2m09暂无昵称, userId=a5002500055, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26291e5101bd, moduleTitle=2019 ESMO胃肠癌世界大会：奥拉帕尼维持治疗改善了BRCA突变的转移性胰腺癌患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26291e5101bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1390222, encodeId=69551390222f3, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, objectTitle=ESMO世界胃肠癌大会：评估脂质体伊立替康作为转移性胰腺癌一线疗法的I/II期临床研究, objectType=article, longId=174987, objectId=88ee1e49876f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88ee1e49876f, replyNumber=0, likeNumber=78, createdTime=2019-07-09, rootId=0, userName=124986d2m09暂无昵称, userId=a5002500055, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88ee1e49876f, moduleTitle=ESMO世界胃肠癌大会：评估脂质体伊立替康作为转移性胰腺癌一线疗法的I/II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88ee1e49876f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1390221, encodeId=520213902217d, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, objectTitle=AACR19：APX005M具有治疗转移性胰腺癌的前景, objectType=article, longId=163457, objectId=c1ec16345ee8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1ec16345ee8, replyNumber=0, likeNumber=83, createdTime=2019-04-04, rootId=0, userName=124986d2m09暂无昵称, userId=a5002500055, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1ec16345ee8, moduleTitle=AACR19：APX005M具有治疗转移性胰腺癌的前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1ec16345ee8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1390220, encodeId=f3a4139022015, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, objectTitle=BTK抑制剂Imbruvica联合化疗未通过III期转移性胰腺癌试验, objectType=article, longId=158889, objectId=58081588897d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58081588897d, replyNumber=0, likeNumber=78, createdTime=2019-01-27, rootId=0, userName=124986d2m09暂无昵称, userId=a5002500055, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58081588897d, moduleTitle=BTK抑制剂Imbruvica联合化疗未通过III期转移性胰腺癌试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58081588897d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

转移性胰腺癌

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#吉西他滨# #白蛋白结合型紫杉醇# #转移性胰腺癌#

减少化疗，疗效相当，还更安全！《柳叶刀》子刊：转移性胰腺癌新治疗策略

2024-09-05发表于上海

124986d2m09暂无昵称 (审核中...)

前往app查看评论内容

#转移性胰腺癌#

Radiology：CT+CA19-9的强强联手：非转移性胰腺癌的治疗反应评估

2022-08-13

124986d2m09暂无昵称 (审核中...)

前往app查看评论内容

#转移性胰腺癌#

Radiology：CT和CA19-9对非转移性胰腺癌治疗效果的评估

2022-07-11

124986d2m09暂无昵称 (审核中...)

前往app查看评论内容

#转移性胰腺癌#

ASCO：转移性胰腺癌患者化疗免疫治疗后生物特征与生存率的关系

2022-06-01

124986d2m09暂无昵称 (审核中...)

前往app查看评论内容

#转移性胰腺癌#

Clin Cancer Res：PARP抑制剂Veliparib联合优化的FOLFIRI作为二线治疗转移性胰腺癌

2021-12-11

124986d2m09暂无昵称 (审核中...)

前往app查看评论内容

#转移性胰腺癌#

ESMO Open：Nab-紫杉醇/吉西他滨和FOLFIRINOX作为一线序贯治疗转移性胰腺癌

2021-12-01

124986d2m09暂无昵称 (审核中...)

前往app查看评论内容

#转移性胰腺癌#

Oncologist: FOLFOX方案联合dasatinib（达沙替尼）一线治疗转移性胰腺癌患者的疗效和安全性

2021-12-01

124986d2m09暂无昵称 (审核中...)

前往app查看评论内容

#转移性胰腺癌#

JNCCN：真实世界研究中转移性胰腺癌患者一线和二线治疗的预后

2021-09-09

124986d2m09暂无昵称 (审核中...)

前往app查看评论内容

#转移性胰腺癌#

Eur J Cancer：3期| 改良版FOLFIRINOX vs S-1方案二线治疗吉西他滨难治性转移性胰腺癌的疗效

2021-09-08

124986d2m09暂无昵称 (审核中...)

前往app查看评论内容

#转移性胰腺癌#

J Clin Oncol：转移性胰腺癌的一线治疗该何去何从？

2021-07-24

124986d2m09暂无昵称 (审核中...)

前往app查看评论内容

#转移性胰腺癌#

JCO：Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效

2021-02-11

124986d2m09暂无昵称 (审核中...)

前往app查看评论内容

#转移性胰腺癌#

Lancet Oncol：CD40激动性单克隆抗体APX005M联合化疗治疗转移性胰腺癌

2021-01-08

124986d2m09暂无昵称 (审核中...)

前往app查看评论内容

#转移性胰腺癌#

FDA授予伊立替康脂质体（ONIVYDE）快速通道指定，用于转移性胰腺癌的一线联合治疗

2020-06-19

124986d2m09暂无昵称 (审核中...)

前往app查看评论内容

#转移性胰腺癌#

NantKwest的NK细胞疗法联合T细胞激活剂在转移性胰腺癌患者的早期临床试验中，将肿瘤根除

2020-01-19

124986d2m09暂无昵称 (审核中...)

前往app查看评论内容

#转移性胰腺癌#

BioLineRx宣布其CXCL4拮抗剂BL-8040与Keytruda联合治疗转移性胰腺癌的2b临床活性

2019-11-08

124986d2m09暂无昵称 (审核中...)

前往app查看评论内容

#转移性胰腺癌#

JAMA Oncol：紫杉醇、吉西他滨以及顺铂治疗转移性胰腺癌

2019-10-10

124986d2m09暂无昵称 (审核中...)

前往app查看评论内容

#转移性胰腺癌#

2019 ESMO胃肠癌世界大会：奥拉帕尼维持治疗改善了BRCA突变的转移性胰腺癌患者的无进展生存期

2019-07-11

124986d2m09暂无昵称 (审核中...)

前往app查看评论内容

#转移性胰腺癌#

ESMO世界胃肠癌大会：评估脂质体伊立替康作为转移性胰腺癌一线疗法的I/II期临床研究

2019-07-09

124986d2m09暂无昵称 (审核中...)

前往app查看评论内容

#转移性胰腺癌#

AACR19：APX005M具有治疗转移性胰腺癌的前景

2019-04-04

124986d2m09暂无昵称 (审核中...)

前往app查看评论内容

#转移性胰腺癌#

BTK抑制剂Imbruvica联合化疗未通过III期转移性胰腺癌试验

2019-01-27

科室
- - 订阅+
  - 更多科室
工具
服务